A New Vision For Healthcare

Empowering Consumers with Advanced Medical Diagnostics

TRANSCRIPT

GRIP’s biosensor technology has the potential to establish a new healthcare norm. User-administered diagnostic testing in the home, telehealth interaction, data-informed diagnosis, and the prompt application of appropriate care with no need for a visit to the clinic.

GRIP has scientific and clinical evidence that this vision of the future is not a dream, but instead a plausible reality. Together, we can make it happen.

Rapid and accurate medical diagnosis is the gate through which personalized healthcare must pass to realize its full potential. Today we stand poised to unlock this gate. The key: leverage the power of GRIP Molecular novel electronic biosensor technology to transform a standard cell phone into a lab-grade medical diagnostic instrument.

GRIP’s technology has the potential to fundamentally alter how numerous diseases and health conditions are detected, diagnosed, monitored, and treated by putting large diagnostic lab capabilities into the hands of consumers and their clinicians. It enables medical diagnostic testing to be performed by anyone, anywhere, at any time.

The GRIP biosensor technology can simultaneously detect multiple disease-causing pathogens and health condition biomarkers in minutes and display these results on the user’s cell phone. These results are then ready for immediate transmission to a healthcare professional, providing them unprecedented levels of timely and actionable diagnostic information.

UNMET NEED

When sickness strikes, it’s always concerning, never convenient, and the unknowns can be a significant source of stress. When sickness does strike, it’s important to quickly and accurately diagnose what is causing the symptoms, so the appropriate treatment can be promptly applied to derive maximum benefit.

Despite noteworthy advances, today’s medical diagnostic tests require significant trade-offs between speed, accuracy, multi-biomarker detection, convenience, and cost. Most diagnostic tests that can be performed in the home do not provide the sensitivity required to detect a disease or health condition in the early stages. And none offer the broad, multi-biomarker diagnostic testing capability required to make well-informed clinical diagnosis. The sophisticated diagnostic testing equipment that does offer these capabilities requires specialized equipment and often the need for skilled operators who work in a clinic or centralized lab environment.

These factors make these tests expensive to utilize, and inconvenient and time-consuming to access. A better solution is required.

SOLUTION

GRIP is pursuing a different approach. Unlike today’s chemical-based diagnostic tests, GRIP uses integrated circuit technology that is enhanced with a layer of graphene to which biological capture molecules are applied using an inkjet printing process. When these capture molecules on the graphene surface bind to a specific biomarker of interest, the electrical dynamics across the graphene change.

GRIP measures these electrical changes, digitizes the signal, and sends it to the cell phone to display the results. This approach offers extraordinary diagnostic capabilities, great flexibility in what combination of biomarkers can be detected, and tremendous production scalability to meet demand as diagnostic needs evolve and new health threats arise.

USAGE

The GRIP system is very easy to use. A barcode on the outer packaging of the GRIP cartridge is first scanned using a standard cell phone to download a proprietary app to display the results. At the time of use, a nasal secretion, saliva, urine, or other appropriate sample is collected with a swab and mixed with a buffer solution that is provided with a cartridge in a flexible container.

The container is then capped and used to inject the solution into the cartridge. The biosensor inside the cartridge immediately interrogates the sample and sends the results to the cell phone for display and transmission.

Numerous cartridge form factors and cell phone connectivity options can be envisioned, each tailored to the typical user and use case. It is important to highlight that the information the clinician will receive from the GRIP system will far surpass what they typically have available today, both in terms of timeliness and data robustness. It will include multi-biomarker detection results, pathogen, variant, and strain identification, and indications of resistance to and appropriateness of various therapies.

Artificial intelligence can be applied to analyze the detailed diagnostic information the grip test provides, which, in combination with other health information about the patient, can be used by the clinician to assess care options, leveraging state-of-the-art medical guidelines.

APPLICATIONS

Identification and treatment of a wide variety of diseases and health conditions will benefit from the application of the GRIP diagnostic technology, including urinary tract infection, sexually transmitted diseases, HIV, herpes, measles, candida infections, upper respiratory infections, and the numerous infections that arise from mosquito transmission.

Beyond the detection of disease-causing pathogens, the GRIP technology can also be used to conveniently detect and monitor various health conditions, including the measurement of hormones associated with fertility and biomarkers associated with heart attack, kidney disease, and concussion.

TRACTION

GRIP has completed extensive research of its electronic biosensor. These have demonstrated its extraordinary biomarker detection capabilities, which are comparable to sophisticated lab-based diagnostic testing equipment. This research evidence has been bolstered with clinical feasibility study results using nasal samples from infected COVID-19 patients. Here again, extraordinary biomarker detection capability was observed.

The future is bright for those who capitalize on the remarkable diagnostic capabilities found at the intersection of biology, electronics, and digital health. GRIP is in the middle of that intersection developing the next generation of medical diagnostic tests that will provide the rapid, accurate and actionable medical diagnostic information we and our doctors need, when and where it matters most – at the point of need.

Please go to our website www.GRIPMolecular.com to learn more about GRIP Molecular and how you may be able to support our efforts.

Stasia Ogden, JD

Stasia Ogden recently joined GRIP in a General Counsel role with a particular expertise in Intellectual Property Law.  Stasia has over 20 years as a practicing attorney in law firms and major multi-national corporations and 9 years with Baxter Healthcare Corporation and 4 years with BD.  Her focus on healthcare industry global IP strategy, transactions, licensing, litigation and global portfolio management will help GRIP navigate global IP issues and maximize existing rights to 3+ patent families that provide the foundation for GRIP’s novel electronic biosensor.  Stasia has a Juris Doctor degree from Georgetown University, an MBA from University of Missouri – St. Louis, and a BA in Biochemistry from Northwestern University in Chicago.

Michael Osterholm PhD

University of Minnesota Regents Professor 
  • McKnight Presidential Endowed Chair in Public Health 
  • Author
  • University of Minnesota
  • Director of the Center for Infectious Disease Research and Policy (CIDRAP)
  • Distinguished Teaching Professor in the Division of Environmental Health Sciences, School of Public Health and Technological Leadership Institute, College of Science and Engineering,
  • Medical School – Adjunct Professor
  • Science Envoy for Health Security on behalf of the US Department of State 2018-19
  • Numerous national/global Advisory Board appointments on Biosecurity, Health Research and Pandemics

Steven Koester PhD

Professor Electrical & Computer Engineering
University of Minnesota

Research Areas:

  • Graphene Biosensors
  • Biomedical & Biological Computational Methods
  • Energy Systems & Power Electronics
  • Micro and Nano structures 

Michael McAlpine, PhD

Professor Mechanical Engineering University of Minnesota

Research Areas:

  • 3D printing functional materials & devices
  • Advanced manufacturing using nanoscale inks
  • Biomedical devices
  • Bioelectronics

Edward Ludwig

  • 45+years of senior executive medical industry leadership experience
  •   Numerous Board roles, including with; Boston Scientific, CVS, Aetna, AdvaMed (Chairman), Johns Hopkins Michael Bloomberg School of Public Health, Hackensack University Medical Center, College of Holy Cross, Columbia Business School, The Center for Higher Ambition Leadership 
  • MBA – Columbia University

Laurie Knutson MBA

Vice President of Marketing

Laurie Knutson is GRIP’s VP of Marketing.  She bring over 30 years of healthcare strategy, product development and systems transformation experience across Fortune 50 to pre-revenue companies. Laurie has held C-level roles healthcare services, products, insurance, financial services and consulting, and was founder or C-level at 4 tech startups.  Laurie’s focus on commercializing products in the healthcare sector is based on her unique ability to assess the market and product adoption variables in areas of unmet needs. Laurie also has 10+ years analytics with care model development for seniors, commercial and vulnerable populations.  Laurie has her MBA in Finance from the University of Minnesota and her BA in Biology from St. Olaf College in Northfield, Minnesota.

Richard G Minicus MBA, MS

Rich Minicus is seasoned Chief Financial Officer with over 30 years in M&A, venture capital investment, and capital markets transactions. Rich brings 21 years in medical technology business development with Becton Dickinson, BD Ventures, and Pfizer which has enabled GRIP to quickly formulate a detailed financial plan beyond what most startups provide to investors. Rich also has 9 years in finance with Merrill Lynch Capital Markets, ML Venture Capital, and JP Morgan. Rich earned his MBA at Harvard Business School, and holds a MS in Biology from Fairleigh Dickinson University.

Caroline Popper

Caroline Popper, MD is the Co-Founder and President, Popper & Co. healthcare consultancy. Caroline has the perfect combination of 30 years’ experience in medical diagnostics and drug discovery, combined with extensive direct clinical experience. She has held many senior managerial and advisory positions with numerous global diagnostics companies, including BD, bioMérieux and MDS Proteomics. Caroline was also an attending physician at the Department of Emergency Medicine at Baltimore’s Johns Hopkins Hospital, where she completed residencies in internal medicine and pathology.

Edward Gillan

CEO, CCO

Ed Gillen is GRIP’s CEO and brings over 30 years medical device industry experience, including point-of-care diagnostics.  Ed enjoyed a successful 23-year career at Becton Dickinson (BD) holding many positions globally including WW Senior Director – Strategy & Business Development – Diabetes Care Division, Global VP/GM – Surgical and Anesthesia Systems ($200M P&L), Advanced Drug Delivery, Global Business Leader – Vaccine Delivery.  Ed’s startup experience includes his most recent role as CEO Medality Medical. Ed has his MBA from Penn State University.

disease diagnosis Grip molecular

Bruce Batten

Founder/Chairman/President

Bruce Batten has been founder / CEO of four technology startups including C-level roles at Thermo Instruments, CyberOptics and Advantek. Bruce started his career in Academia earning a Ph.D. in Anatomy & Cell Biology at the Medical College of Virginia, post-doctoral work at Harvard Medical School. He was Faculty member at Harvard, Tufts and The Ohio State medical schools and later ran the MBA Program at Augsburg University. Bruce has over 10 years of molecular diagnostic development, including detailed work on a POC Zika virus assay. Bruce founded GRIP Molecular to commercialize breakthrough solid state bioelectronic technology that will disrupt the diagnostic industry and empower consumers and doctors with fast, accurate and comprehensive information.

Linkedin